Nonamyloid PET Biomarkers and Alzheimer's Disease

109 16
´╗┐Nonamyloid PET Biomarkers and Alzheimer's Disease

Limitations of Nonamyloid PET Biomarkers for AD


A majority of PET radiotracers targeting nonamyloid processes are labeled with carbon-11 (11-C), which stands as a limitation owing to the short (~20 min) half-life of this isotope. Production of 11-C radioligands is therefore limited to imaging centers possessing an onsite cyclotron and a radiochemistry department with the requisite expertise, making the cost of studies prohibitive for routine clinical use. Though fluorine-18 radiopharmaceuticals have been introduced-with a half-life of approximately 110 min allowing for centralized production and regional distribution-only [F]FDG is currently approved for clinical use. In the case of TSPO ligands, their clinical utility may further be hampered by differential binding affinity among carriers of a common single-nucleotide polymorphism (rs6971) in exon 4 of the TSPO gene. The issue of specificity for AD likewise stands as a limitation owing to the presence of neuroinflammation, deposition of hyperphosphorylated tau, dysregulation of neurotransmitter systems and hypometabolic changes across a wide range of neurodegenerative diseases (for review, see).

Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
You can unsubscribe at any time

Leave A Reply

Your email address will not be published.